Benzinga·3h ago·NaHemab Therapeutics Prices $346.7M IPO as Blood Disorder Biotech Debuts on NasdaqHemab Therapeutics raised $346.7M in upsized IPO, pricing 19.3M shares at $18 with full underwriter exercise. COAGIPOclinical-stage
Benzinga··Na